Therefore, although further investigation is required, our results demonstrate the possibility that activation of the YY1/PGC-1β axis might be crucial for liver metabolic disorder diseases, and that it might be a potential driver of HCC development from hepatic steatosis. This evidence concerns the gene PPARGC1B and hepatocellular carcinoma.